Exploring the Brain - Gut Microbiota - Kidney Interactive Damage Mechanisms Underlying Cognitive Decline in Patients With IgA Nephropathy Using Ultra-high Field Magnetic Resonance Imaging
NCT07617402, Completed, Tang-Du Hospital
Trial 8
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Exploring the Brain - Gut Microbiota - Kidney Interactive Damage Mechanisms Underlying Cognitive Decline in Patients With IgA Nephropathy Using Ultra-high Field Magnetic Resonance Imaging | ClinicalTrials.gov |
| NCT number | NCT07617402 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Enrollment | 200 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Tang-Du Hospital | ClinicalTrials.gov |
| Conditions | IgA Nephropathy (IgAN) | ClinicalTrials.gov |
| First posted | 2026-06-01 | ClinicalTrials.gov |
| Last updated | 2026-06-01 | ClinicalTrials.gov |
Registered outcomes 7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Gut Microbiome Metagenomic Characteristics | April 2025 to March 2027 | Description: Taxonomic composition, relative abundance of microbial taxa, alpha diversity indices (Shannon, Simpson), and functional pathway profiles derived from shotgun metagenomic sequencing of fecal samples. Unit/Scale: Relative abundance (%), Shannon index, Simpson index, normalized pathway abundance. | ClinicalTrials.gov |
| Primary | Functional Neuroimaging Indices | April 2025 to March 2027 | Description: Resting-state functional magnetic resonance imaging (rs-fMRI) derived metrics, including functional connectivity (FC), amplitude of low-frequency fluctuation (ALFF), fractional ALFF (fALFF), and regional homogeneity (ReHo). Unit/Scale: Standardized Z-scores, correlation coefficients. | ClinicalTrials.gov |
| Primary | Cognitive Function Scores | April 2025 to March 2027 | Description: Cognitive performance assessed using the Montreal Cognitive Assessment (MoCA). Scale/Range: 0-30 points. Interpretation: Higher scores indicate better cognitive function; lower scores indicate more severe cognitive impairment. | ClinicalTrials.gov |
| Secondary | Serum Metabolomic and Biomarker Levels | April 2025 to March 2027 | Description: Quantitative analysis of serum metabolomic profiles, inflammatory factors (e.g., IL-6, TNF-α), and neurotransmitters (e.g., serotonin, dopamine) using targeted metabolomics assays. Unit/Scale: pg/mL, ng/mL, or standardized relative concentration units. | ClinicalTrials.gov |
| Secondary | Fecal Gut Microbiome Analysis | April 2025 to March 2027 | Description: Taxonomic composition, alpha/beta diversity, and differential microbial taxa identified via 16S rRNA gene sequencing or shotgun metagenomic sequencing of fecal samples. Unit/Scale: Relative abundance (%), Shannon index, Simpson index, Bray-Curtis dissimilarity. | ClinicalTrials.gov |
| Secondary | Memory Function (Cognitive Subdomain) | April 2025 to March 2027 | Description: Verbal memory assessed using the Auditory Verbal Learning Test (AVLT). Scale/Range: 0-75 points (AVLT total recall score). Interpretation: Higher scores indicate better memory performance. | ClinicalTrials.gov |
| Secondary | Attention and Executive Function (Cognitive Subdomains) | April 2025 to March 2027 | Description: Attention and executive function assessed using the Stroop Color-Word Test and Trail Making Test (TMT). Unit/Scale: Reaction time (seconds), completion time (seconds), number of errors. Interpretation: Shorter completion time and fewer errors indicate better attention and executive function. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)